PW
Pamela Wapnick
Chief Financial Officer

Pamela Wapnick insider trades: Metagenomi Therapeutics (MGX) stock sales

Chief Financial Officer, Metagenomi Therapeutics Last trade Jun 5, 2026 11 Form 4 filings
$9K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Pamela reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 5, 2026MGX↓ Sell$4K
Mar 5, 2026MGX↓ Sell$3K
Dec 5, 2025MGX↓ Sell$3K
Sep 5, 2025MGX↓ Sell$3K
Jun 6, 2025MGX↓ Sell$3K
Mar 5, 2025MGX↓ Sell$3K
Dec 5, 2024MGX↓ Sell$3K
Sep 5, 2024MGX↓ Sell$18K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other MGX insiders

Open-market trades in the last 12 months

About Pamela Wapnick's insider trades

Pamela Wapnick is Chief Financial Officer at Metagenomi Therapeutics (MGX). Since Sep 5, 2024, Pamela has reported no open-market purchases and 8 sales worth $39K on SEC Form 4. In the last 12 months: 3 sales ($9K).

Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MGX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.